Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major seasonal influenza markets reached a value of US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 41.6 Billion by 2034, exhibiting a growth rate (CAGR) of 15.08% during 2024-2034.
The seasonal influenza market has been comprehensively analyzed in IMARC's new report titled "Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Seasonal influenza, commonly referred to as flu, is a contagious respiratory disorder caused by the influenza viruses. It typically occurs in seasonal outbreaks, mainly during the fall and winter months in temperate regions. This condition spreads through respiratory droplets when an infected person coughs, sneezes, or talks. It can also be transmitted by coming into contact with contaminated surfaces and then touching the mouth, nose, or eyes. The common symptoms of this ailment include fever, body aches, runny or stuffy nose, fatigue, cough, loss of appetite, weakness, diarrhea, sore throat, vomiting, nausea, chills, headaches, etc. The diagnosis of seasonal influenza typically involves a combination of a medical history review, clinical feature assessment, and laboratory procedures. During an initial exam, the healthcare provider may evaluate lung function and check for other physical indicators of respiratory illness. Additionally, rapid influenza diagnostic tests (RIDTs) are recommended to validate the presence of viral antigens in patients. Numerous molecular techniques, such as reverse transcription-polymerase chain reaction and nucleic acid amplification tests, are further utilized to obtain details about viral load and strain characterization.
The increasing cases of airborne diseases due to various factors, including cold weather, dry air, enhanced crowding in enclosed spaces, etc., are primarily driving the seasonal influenza market. In addition to this, the rising prevalence of weakened immunity that can impair the respiratory tract's natural defense mechanisms, making individuals more susceptible to viral infections, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antiviral drugs, like oseltamivir, zanamivir, peramivir, etc., to reduce the severity and duration of flu symptoms among patients is further bolstering the market growth. Apart from this, the inflating application of saline nasal spray, which works by flushing out mucus and irritants from the nasal passages to relieve congestion, minimize post-nasal drip, and alleviate sinus discomfort, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of chemoprophylaxis techniques, since they can effectively reduce the risk of acquiring viral infections, thereby slowing down the spread of the disease, is expected to drive the seasonal influenza market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the seasonal influenza market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for seasonal influenza and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the seasonal influenza market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the seasonal influenza market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the seasonal influenza market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current seasonal influenza marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the seasonal influenza market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the seasonal influenza market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the seasonal influenza market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of seasonal influenza across the seven major markets?
What is the number of prevalent cases (2018-2034) of seasonal influenza by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of seasonal influenza by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of seasonal influenza by type across the seven major markets?
How many patients are diagnosed (2018-2034) with seasonal influenza across the seven major markets?
What is the size of the seasonal influenza patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of seasonal influenza?
What will be the growth rate of patients across the seven major markets?
Seasonal Influenza: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for seasonal influenza drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the seasonal influenza market?
What are the key regulatory events related to the seasonal influenza market?
What is the structure of clinical trial landscape by status related to the seasonal influenza market?
What is the structure of clinical trial landscape by phase related to the seasonal influenza market?
What is the structure of clinical trial landscape by route of administration related to the seasonal influenza market?
The seasonal influenza market has been comprehensively analyzed in IMARC's new report titled "Seasonal Influenza Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Seasonal influenza, commonly referred to as flu, is a contagious respiratory disorder caused by the influenza viruses. It typically occurs in seasonal outbreaks, mainly during the fall and winter months in temperate regions. This condition spreads through respiratory droplets when an infected person coughs, sneezes, or talks. It can also be transmitted by coming into contact with contaminated surfaces and then touching the mouth, nose, or eyes. The common symptoms of this ailment include fever, body aches, runny or stuffy nose, fatigue, cough, loss of appetite, weakness, diarrhea, sore throat, vomiting, nausea, chills, headaches, etc. The diagnosis of seasonal influenza typically involves a combination of a medical history review, clinical feature assessment, and laboratory procedures. During an initial exam, the healthcare provider may evaluate lung function and check for other physical indicators of respiratory illness. Additionally, rapid influenza diagnostic tests (RIDTs) are recommended to validate the presence of viral antigens in patients. Numerous molecular techniques, such as reverse transcription-polymerase chain reaction and nucleic acid amplification tests, are further utilized to obtain details about viral load and strain characterization.
The increasing cases of airborne diseases due to various factors, including cold weather, dry air, enhanced crowding in enclosed spaces, etc., are primarily driving the seasonal influenza market. In addition to this, the rising prevalence of weakened immunity that can impair the respiratory tract's natural defense mechanisms, making individuals more susceptible to viral infections, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective antiviral drugs, like oseltamivir, zanamivir, peramivir, etc., to reduce the severity and duration of flu symptoms among patients is further bolstering the market growth. Apart from this, the inflating application of saline nasal spray, which works by flushing out mucus and irritants from the nasal passages to relieve congestion, minimize post-nasal drip, and alleviate sinus discomfort, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of chemoprophylaxis techniques, since they can effectively reduce the risk of acquiring viral infections, thereby slowing down the spread of the disease, is expected to drive the seasonal influenza market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the seasonal influenza market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for seasonal influenza and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the seasonal influenza market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the seasonal influenza market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the seasonal influenza market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current seasonal influenza marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the seasonal influenza market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the seasonal influenza market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the seasonal influenza market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of seasonal influenza across the seven major markets?
What is the number of prevalent cases (2018-2034) of seasonal influenza by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of seasonal influenza by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of seasonal influenza by type across the seven major markets?
How many patients are diagnosed (2018-2034) with seasonal influenza across the seven major markets?
What is the size of the seasonal influenza patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of seasonal influenza?
What will be the growth rate of patients across the seven major markets?
Seasonal Influenza: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for seasonal influenza drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the seasonal influenza market?
What are the key regulatory events related to the seasonal influenza market?
What is the structure of clinical trial landscape by status related to the seasonal influenza market?
What is the structure of clinical trial landscape by phase related to the seasonal influenza market?
What is the structure of clinical trial landscape by route of administration related to the seasonal influenza market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEASONAL INFLUENZA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEASONAL INFLUENZA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEASONAL INFLUENZA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 SEASONAL INFLUENZA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEASONAL INFLUENZA - UNMET NEEDS
10 SEASONAL INFLUENZA - KEY ENDPOINTS OF TREATMENT
11 SEASONAL INFLUENZA - MARKETED PRODUCTS
11.1 List of Seasonal Influenza Marketed Drugs Across the Top 7 Markets
11.1.1 Tamiflu (Oseltamivir) - Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Relenza (Zanamivir) - Vaxart/GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Rapivab (Peramivir) - BioCryst Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xofluza (Baloxavir marboxil) - Roche/Shionogi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEASONAL INFLUENZA - PIPELINE DRUGS
12.1 List of Seasonal Influenza Pipeline Drugs Across the Top 7 Markets
12.1.1 mRNA1011 - Moderna Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 mRNA1030 - Moderna Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 mRNA 1010 - Moderna Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 VXA A1 1 - Vaxart
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEASONAL INFLUENZA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEASONAL INFLUENZA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEASONAL INFLUENZA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Seasonal Influenza - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Seasonal Influenza - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Seasonal Influenza - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Seasonal Influenza - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Seasonal Influenza - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Seasonal Influenza - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Seasonal Influenza - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Seasonal Influenza - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Seasonal Influenza - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Seasonal Influenza - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Seasonal Influenza - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Seasonal Influenza - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Seasonal Influenza - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Seasonal Influenza - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Seasonal Influenza - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Seasonal Influenza - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Seasonal Influenza - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Seasonal Influenza - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Seasonal Influenza - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Seasonal Influenza - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Seasonal Influenza - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Seasonal Influenza - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Seasonal Influenza - Access and Reimbursement Overview
16 SEASONAL INFLUENZA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEASONAL INFLUENZA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEASONAL INFLUENZA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SEASONAL INFLUENZA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SEASONAL INFLUENZA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SEASONAL INFLUENZA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 SEASONAL INFLUENZA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SEASONAL INFLUENZA - UNMET NEEDS
10 SEASONAL INFLUENZA - KEY ENDPOINTS OF TREATMENT
11 SEASONAL INFLUENZA - MARKETED PRODUCTS
11.1 List of Seasonal Influenza Marketed Drugs Across the Top 7 Markets
11.1.1 Tamiflu (Oseltamivir) - Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Relenza (Zanamivir) - Vaxart/GlaxoSmithKline
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Rapivab (Peramivir) - BioCryst Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Xofluza (Baloxavir marboxil) - Roche/Shionogi
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SEASONAL INFLUENZA - PIPELINE DRUGS
12.1 List of Seasonal Influenza Pipeline Drugs Across the Top 7 Markets
12.1.1 mRNA1011 - Moderna Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 mRNA1030 - Moderna Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 mRNA 1010 - Moderna Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 VXA A1 1 - Vaxart
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. SEASONAL INFLUENZA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SEASONAL INFLUENZA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SEASONAL INFLUENZA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Seasonal Influenza - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Seasonal Influenza - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Seasonal Influenza - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Seasonal Influenza - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Seasonal Influenza - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Seasonal Influenza - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Seasonal Influenza - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Seasonal Influenza - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Seasonal Influenza - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Seasonal Influenza - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Seasonal Influenza - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Seasonal Influenza - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Seasonal Influenza - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Seasonal Influenza - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Seasonal Influenza - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Seasonal Influenza - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Seasonal Influenza - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Seasonal Influenza - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Seasonal Influenza - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Seasonal Influenza - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Seasonal Influenza - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Seasonal Influenza - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Seasonal Influenza - Access and Reimbursement Overview
16 SEASONAL INFLUENZA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SEASONAL INFLUENZA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SEASONAL INFLUENZA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
